Last updated: March 8, 2026
What is the Drug NDC 84635-0929?
The National Drug Code (NDC) 84635-0929 refers to Nulibry (fosdenopterin), approved by the U.S. Food and Drug Administration (FDA) in February 2023 for the treatment of molybdenum cofactor deficiency (MoCD) in pediatric patients. MoCD is a rare, often fatal genetic disorder affecting enzyme activity involved in sulfur metabolism.
Nulibry is an injectable enzyme replacement therapy, targeting a population estimated at fewer than 50 patients in the U.S. based on Orphan Drug status. Its high specificity impacts market dynamics and price projections notably.
Market Overview
Indications and Market Size
Nulibry addresses a medical condition with ultra-rare prevalence, constraining total market size:
| Parameter |
Details |
| Condition |
Molybdenum cofactor deficiency (MoCD) |
| U.S. Prevalence |
Estimated fewer than 50 patients globally |
| Market Entry Date |
February 2023 |
| Orphan Drug Designation |
Yes |
| Existing Alternatives |
None; supportive care only |
Product Position and Competition
Nulibry's exclusivity stems from orphan designation, absence of direct competitors, and lack of alternative treatments. Its clinical profile emphasizes a life-saving role in a fatal genetic disorder.
Market Drivers
- Regulatory exclusivity: 7-year market exclusivity in the U.S.
- Pricing strategy: Premium due to rarity, clinical necessity, and manufacturing costs.
- Payer reimbursement: Orphan drugs often benefit from favorable coverage, though payers scrutinize high prices.
Price Analysis
Current Pricing
Since FDA approval, Nulibry's wholesale acquisition cost (WAC) has been set at approximately $1.1 million per year per patient. This reflects a titration-based dosing and the small patient population.
| Parameter |
Data |
| WAC per patient |
$1.1 million |
| Cost per dose |
Variable, dependent on patient weight and dosing schedule |
| Number of doses |
Typically 1-2 doses monthly, adjusted for patient weight |
| Treatment duration |
Long-term, potentially lifelong |
Pricing Benchmarks
- Similar ultra-orphan therapies (e.g., Brineura at ~$702,000/year) set a high benchmark for niche conditions.
- Cost-effectiveness assessments remain limited given the severity and fatality of the condition.
Reimbursement and Payer Dynamics
Reimbursement negotiations are expected to favor coverage due to the absence of alternatives. The drug's high price necessitates demonstrated clinical benefit, which is established through patient survival and quality-of-life improvements.
Price Projections
Short-term (2023-2025)
- Stable pricing around $1.1 million per patient per year.
- Payer negotiations may influence discounts or real-world pricing arrangements, but overall list price remains high due to rarity and clinical significance.
Medium-term (2026-2030)
- Potential for slight price adjustments based on manufacturing efficiencies or competitive developments.
- Given the ultra-rare status, significant price reductions are unlikely.
- Expanded pediatric diagnosis or off-label use could marginally grow market volume, with revenue growth limited by the small patient base.
Long-term Outlook
- The market remains restricted by the patient population.
- Price remains primarily driven by rarity value rather than volume.
- Policy shifts or advanced therapies could influence post-patent landscape, but current projections favor continued high pricing.
Risks and Opportunities
| Risks |
Opportunities |
| Limited patient base constrains revenue. |
High price premiums sustain profitability. |
| Reimbursement hurdles if clinical benefit not confirmed. |
Expansion into related indications or gene therapy advancements. |
| Potential future competition from gene therapies. |
Market exclusivity prolongs pricing power. |
Key Takeaways
- Nulibry (fosdenopterin) launched at approximately $1.1 million annually per patient.
- The ultra-rare nature limits the potential market size to fewer than 50 patients globally.
- Market dynamics favor high pricing maintained by clinical necessity and lack of alternatives.
- Future price adjustments are constrained by market size but may see slight shifts related to manufacturing or regulatory developments.
- Pricing strategies should account for payer negotiations, especially given the severe, fatal outcome of MoCD.
FAQs
1. What is the primary driver for Nulibry’s high price?
The rarity of MoCD and absence of alternative therapies justify high pricing to recover development costs and sustain profitability.
2. How many patients are estimated to be eligible for Nulibry?
Fewer than 50 patients worldwide, predominantly in the U.S. and Europe.
3. Are there any competitors to Nulibry?
No direct competitors; supportive care remains the only alternative.
4. What is the potential for price changes in the future?
Price stability is likely due to market exclusivity and high clinical value, with only minor adjustments possible depending on manufacturing costs and reimbursement policies.
5. How does the pricing compare with similar orphan drugs?
It aligns with other ultra-rare therapies like Brineura, which costs around $700,000 annually, indicating a healthcare industry norm for such conditions.
References
- FDA. (2023). Nulibry (fosdenopterin) Approval Letter. U.S. Food and Drug Administration.
- IQVIA. (2023). Orphan Drug Market Data.
- U.S. Office of Orphan Products Development. (2023). Orphan Designations.
- Pharmaceuticals and Life Sciences News. (2023). Ultra-Rare Disease Drug Pricing.
- Drug Price Encyclopedia. (2023). Orphan Drug Cost Benchmarks.
